文献速递贫血与红细胞疾病血栓与止血

低剂量西达本胺恢复免疫性血小板减少症小鼠和人类的免疫耐受

Low-dose chidamide restores immune tolerance in ITP in mice and humans.
PubMed 文献 · Blood · 2018-12-14

研究通过体外和体内实验发现,低剂量组蛋白去乙酰化酶抑制剂西达本胺可减轻被动和主动小鼠ITP模型的血小板减少,减弱巨噬细胞对包被血小板的吞噬,促进Foxp3+调节性T细胞产生与转化并恢复其抑制功能,且经调节组蛋白H3K27乙酰化调控CTLA4表达;阻断CTLA4可抵消上述效应。作者据此提出低剂量西达本胺有潜力成为ITP的新型临床治疗。

要点

  • 低剂量西达本胺减轻被动和主动小鼠ITP模型的血小板减少。
  • 低剂量HDACi减弱巨噬细胞吞噬抗体包被血小板,促进Foxp3+ Treg产生与转化。
  • 低剂量HDACi经组蛋白H3K27乙酰化调控PBMC中CTLA4表达,阻断CTLA4可抵消其效应。

核心结论

  • 作者提出低剂量西达本胺给药有潜力作为ITP的新型临床治疗。

研究设计与样本

  • 研究进行体外和体内实验,使用被动和主动小鼠ITP模型,并涉及人类样本。

主要发现

  • 低剂量西达本胺减轻被动和主动小鼠ITP模型的血小板减少。
  • 低剂量HDACi减弱巨噬细胞对包被血小板的吞噬,刺激天然Foxp3+ Treg细胞产生,促进T细胞向Treg细胞的外周转分化,并在体内和体外恢复Treg细胞抑制功能。
  • 低剂量HDACi通过调节组蛋白H3K27乙酰化调控外周血单个核细胞中CTLA4表达。
  • 阻断CTLA4可抵消低剂量HDACi对ITP的治疗效应。

临床怎么用

  • 作者提出低剂量西达本胺给药有潜力作为ITP的新型临床治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Increased macrophage phagocytosis of antibody-coated platelets, as well as decreased numbers and/or impaired function of CD4+CD25+Foxp3+ regulatory T (Treg) cells, has been shown to participate in the pathogenesis of immune thrombocytopenia (ITP). Low-dose histone deacetylase inhibitors (HDACi's) are anti-inflammatory and immunomodulatory agents that can enhance immunosuppression in graft-versus-host disease by increasing the number and function of Foxp3+ Treg cells, but it is unclear whether they have the potential to promote immune tolerance and platelet release in ITP. In this study, we performed in vitro and in vivo experiments and found that a low-dose HDACi (chidamide) alleviated thrombocytopenia in passive and active murine models of ITP. Further, low-dose HDACi's attenuated macrophage phagocytosis of antibody-coated platelets, stimulated the production of natural Foxp3+ Treg cells, promoted the peripheral conversion of T cells into Treg cells, and restored Treg cell suppression in vivo and in vitro. Finally, we confirmed that low-dose HDACi's could regulate CTLA4 expression in peripheral blood mononuclear cells through modulation of histone H3K27 acetylation. Low-dose HDACi treatment in ITP could be offset by blocking the effect of CTLA4. Therefore, we propose that low-dose chidamide administration has potential as a novel treatment for ITP in the clinic.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Zhao HY, Ma YH, Li DQ, et al. Low-dose chidamide restores immune tolerance in ITP in mice and humans. Blood. 2018. PMID: 30552097. doi:10.1182/blood-2018-05-847624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。